Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58

Clinical and Vaccine Immunology

Volumn 21, Issue 4, 2014, Pages 587-593

  Brown, Martha J ^a   Seitz, Hanna ^b,c   Towne, Victoria ^a   Müller, Martin ^b   Finnefrock, Adam C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CONFORMATION; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; DIAGNOSTIC USE; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; MICE; MICE, INBRED BALB C; PAPILLOMAVIRIDAE;

EID: 84897941015     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00773-13     Document Type: Article

References (24)

1. Dunne EF, Datta SD, Markowitz EL. 2008. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer 113:2995-3003. http://dx.doi.org/10.1002/cncr.23763.
2. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 89:12180-12184. http://dx.doi.org/10.1073/pnas.89.24.12180. (Pubitemid 23004809)
3. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gissmann L, Lowy DR, Schiller JT. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936. (Pubitemid 23343814)
4. Muñoz N, Méndez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Muñoz Á. 2004. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis. 190:2077-2087. http://dx.doi.org/10.1086/425907. (Pubitemid 39636354)
5. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki A-B, Fukumoto L. 2002. External genital warts: diagnosis, treatment, and prevention. Clin. Infect. Dis. 35(Suppl 2):S210-224. http://dx.doi.org/10.1086/342109. (Pubitemid 35178333)
6. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin. Diagn. Lab. Immunol. 10:108-115. http://dx.doi.org/10.1128/CDLI.10.1.108-115.2003. (Pubitemid 36133838)
7. Dias D, Doren JV, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin. Diagn. Lab. Immunol. 12:959-969. http://dx.doi.org/10. 1128/CDLI.12.8 .959-969.2005.
8. Pastrana DV, Buck CB, Pang Y-YS, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216. http://dx.doi.org/10.1016/j.virol. 2003.12.027. (Pubitemid 38406035)
9. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. 1990. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J. Virol. 64:5678-5681. (Pubitemid 20364570)
10. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS. 2007. Crystal structures of four types of human papillomavirus L1 capsid proteins. J. Biol. Chem. 282:31803-31811. http://dx.doi.org/10.1074/jbc. M706380200.
11. Rizk RZ, Christensen ND, Michael KM, Müller M, Sehr P, Waterboer T, Pawlita M. 2008. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J. Gen. Virol. 89:117-129. http://dx.doi.org/10.1099/vir. 0.83145-0.
12. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan, JT. 2008. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil, a vaccine for human papillomavirus types 16, 18, 6, and 11. Hum. Vaccin. 4:134-142. http://dx.doi.org/10.4161/hv.4.2.5261. (Erratum, Hum. Vaccin. Immunother. 9:938, 2013, http://dx.doi.org/10 .4161/hv.24581.)
13. Zhao Q, Modis Y, High K, Towne V, Meng Y, Wang Y, Alexandroff J, Brown M, Carragher B, Potter CS, Abraham D, Wohlpart D, Kosinski M, Washabaugh MW, Sitrin RD. 2012. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol. J. 9:52. http://dx.doi.org/10.1186/1743-422X-9-52.
14. Towne V, Zhao Q, Brown M, Finnefrock AC. 2013. Pairwise antibody footprinting using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization. J. Immunol. Methods 388:1-7. http://dx.doi.org/10.1016/j.jim. 2012.11.005.
15. Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Müller L, Pawlita M, Müller M. 2013. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 8:e75677. http://dx.doi.org/10.1371/journal.pone. 0075677.
16. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119:445-462. http://dx.doi.org/10.1385/1-59259-982-6:445.
17. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi L. 2006. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J. Pharm. Sci. 95:2195-2206. http://dx.doi.org/10.1002/jps.20696. (Pubitemid 44568530)
18. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, Kosinski M, Washabaugh MW, Sitrin R, Barr E. 2007. GARDASIL: prophylactic human papillomavirus vaccine development-from bench top to bedside. Clin. Pharmacol. Ther. 81:259-264. http://dx.doi.org/10.1038/sj.clpt.6100055. (Pubitemid 46174823)
19. Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R, Schultz L, Teyral J, Capen R, Oswald CB, Wang Y, Washabaugh M, Jansen K, Sitrin R. 2005. Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples. Hum. Vaccin. 1:191-197. http://dx.doi.org/10.4161/ hv.1.5.2126.
20. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. 2011. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate crossprotection. Vaccine 29:2011-2014. http://dx.doi.org/10.1016/j.vaccine.2011.01.001.
21. Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. 2012. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. Vaccine 31:165-170. http://dx.doi.org/10.1016/j.vaccine.2012.10.067.
22. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT. 2007. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum. Vaccin. 3:109-115. http://dx.doi.org/10.4161/hv.3.4.4058. (Pubitemid 47501028)
23. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27. http://dx.doi.org/10. 1016/j.virol.2004.03.033. (Pubitemid 38737395)
24. de Villiers E-M. 2013. Cross-roads in the classification of papillomaviruses. Virology 445:2-10. http://dx.doi.org/10.1016/j.virol.2013.04. 023.